Insmed INSM 2024 JPMorgan Healthcare Conference

Insmed presented at the J.P. Morgan Healthcare Conference in January 2024, discussing its rare disease pipeline including ARIKAYCE (amikacin liposome inhalation suspension) for nontuberculous mycobacteria infections and clinical-stage programs brensocatib and TPIP. The company addresses regulatory approval strategies, commercialization challenges, and market adoption risks for its approved and investigational therapies.